a prognostic impact of interleukin 17 (il-17) as an immune-marker in patients with bladder cancer

Urinary bladder cancer is a worldwide health issue and the ninth most prevalent cancer across the globe, accounting for almost two-thirds of all urinary malignancies. interleukin 17 (il-17) is a proinflammatory cytokine with pivotal modulatory effects on antitumor immune responses and has been reported to play a prominent role in the occurrence and development of bladder cancer. the present study aimed to measure the quantitative serum and urine levels of il-17 in patients with bladder cancer. blood and urine samples were obtained from 50 diagnosed bladder cancers and 96 healthy people as a control group. the serum and urine level of il-17 was evaluated using an enzyme-linked immunosorbent assay. it has been revealed that the level of il-17 was higher in all patients, as compared to that in controls. these results indicated that this interleukin is an indicator to predict the progression or recurrence of the disease.